New pain drug, Vertex’s Journavx, gets FDA approval as safer alternative to addictive opioids
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
Healio5h
FDA approves nonopioid Journavx for moderate to severe acute pain
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
What's Happening With VRTX Stock?
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...